文献速递银屑病与炎症性皮肤病

Brodalumab治疗银屑病120周长期疗效与安全性:AMAGINE-2随机双盲安慰剂和活性对照III期试验结果

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
PubMed 文献 · J Am Acad Dermatol · 2019-06-05

AMAGINE-2试验评估Brodalumab治疗中重度斑块状银屑病至120周的疗效与安全性。接受Brodalumab 210 mg每2周治疗的患者中,84.4%、75.6%和61.1%分别达到PASI 75、90和100应答(观察数据分析)。安全性至120周与盲法研究期相当,Brodalumab耐受良好且疗效持续超过2年。

要点

  • Brodalumab 210 mg每2周治疗至120周,观察数据分析PASI 75应答率达84.4%。
  • 先前接受Ustekinumab治疗52周后换用Brodalumab,皮肤清除应答与持续Brodalumab治疗相似。
  • 安全性至120周与盲法研究期相当,Brodalumab耐受良好。

核心结论

  • Brodalumab耐受良好,在超过2年的治疗中显示出稳健疗效。

研究设计与样本

  • 随机、双盲、安慰剂和活性对照III期AMAGINE-2试验,评估Brodalumab治疗中重度斑块状银屑病至120周。
  • 患者接受Ustekinumab至52周后换用Brodalumab 210 mg每2周、持续Brodalumab 210 mg每2周或任意剂量Brodalumab。

主要发现

  • 接受Brodalumab 210 mg每2周的患者中,84.4%、75.6%和61.1%在120周时分别达到PASI 75、90和100改善(观察数据分析)。
  • 先前接受Ustekinumab 52周后换用Brodalumab 210 mg每2周的患者,皮肤清除应答与持续Brodalumab 210 mg每2周治疗的患者相似。
  • 安全性至120周与盲法研究期相当。

关键数值与推荐

  • 120周时PASI 75、90、100应答率分别为84.4%、75.6%、61.1%(观察数据分析,Brodalumab 210 mg每2周)。

临床怎么用

  • Brodalumab 210 mg每2周可用于中重度斑块状银屑病的长期治疗,疗效可维持超过2年。
  • 从Ustekinumab转换至Brodalumab 210 mg每2周可获得与持续Brodalumab治疗相似的皮肤清除应答。

局限性

  • 研究末期大量脱落(最后6个月脱落率达31%),导致观察数据分析与非应答者填补分析结果存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. OBJECTIVE: To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial. METHODS: Patients received ustekinumab through week 52 followed by brodalumab 210 mg every 2 weeks, continuous brodalumab 210 mg every 2 weeks, or any dose of brodalumab. Efficacy data were reported through 120 weeks by using observed data, last observation carried forward, and nonresponder imputation analyses. RESULTS: Of patients who received brodalumab 210 mg every 2 weeks, 84.4%, 75.6%, and 61.1% achieved 75%, 90%, and 100% improvement from baseline in Psoriasis Area and Severity Index at 120 weeks (observed data analysis), respectively. Patients who received brodalumab 210 mg every 2 weeks after receiving ustekinumab through 52 weeks achieved a similar skin clearance response as patients who received continuous brodalumab 210 mg every 2 weeks. Safety through 120 weeks was comparable to that of the blinded study periods. LIMITATIONS: A large number of discontinuations toward the end of the study (31% in the final 6 months) were due to early termination and led to differences between observed data and nonresponder imputation results. CONCLUSIONS: Brodalumab is well tolerated and showed robust efficacy for more than 2 years.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2019. PMID: 31175909. doi:10.1016/j.jaad.2019.05.095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。